Local Recurrence in Choroidal Melanomas following Robotic-Assisted Radiosurgery (CyberKnife).
Choroidal melanoma
CyberKnife
Metastasis
Radiation treatment
Recurrence treatment
Survival
Journal
Ocular oncology and pathology
ISSN: 2296-4681
Titre abrégé: Ocul Oncol Pathol
Pays: Switzerland
ID NLM: 101656139
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
24
06
2022
accepted:
31
10
2022
entrez:
17
3
2023
pubmed:
18
3
2023
medline:
18
3
2023
Statut:
ppublish
Résumé
Tumor recurrence in choroidal melanoma has been associated with decreased overall survival due to metastatic spreading. To detect risk factors of local recurrence and side effects, we analyzed tumor planning and treatment parameters in patients with recurrence of choroidal melanoma after treatment with robotic-assisted radiosurgery (CyberKnife). Six hundred ninety-four patients treated with CyberKnife between 2005 and 2019 were retrospectively reviewed. Age, gender, best-corrected visual acuity, tumor height, and diameter were recorded. Treatment planning and radiation doses were reviewed. Salvage therapy, overall survival, metastasis, and complications were recorded. Seventy-four patients showed local recurrence. Local recurrence occurred after 42.1 months post CyberKnife treatment (mean; range: 5-100 months). Fourteen out of 74 patients (18.9%) died during follow-up. Recurrence treatment included enucleation in 51 patients (68.9%) and radiosurgery in 19 patients (25.7%). Treatment planning without contrast medium MRI, radiation dose of less than 21 Gy, and insufficient margin delineation were identified as risk factors incrementing local control. Robotic-assisted radiosurgery (CyberKnife) is a suitable treatment option for large choroidal melanoma up to 12 mm. Patients with significantly better visual acuity received repeat CyberKnife treatment as salvage therapy and showed an eye retention rate of 81%.
Identifiants
pubmed: 36925728
doi: 10.1159/000527915
pii: oop-0008-0221
pmc: PMC10013483
doi:
Types de publication
Journal Article
Langues
eng
Pagination
221-229Informations de copyright
Copyright © 2022 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Arch Ophthalmol. 1997 Aug;115(8):1014-8
pubmed: 9258223
Ophthalmology. 2012 May;119(5):1073-7
pubmed: 22297030
Br J Ophthalmol. 2013 Jul;97(7):804-11
pubmed: 23645818
Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):381-5
pubmed: 8420891
Ophthalmology. 1991 Jun;98(6):984-8
pubmed: 1866154
Technol Cancer Res Treat. 2008 Oct;7(5):369-74
pubmed: 18783286
Br J Ophthalmol. 2010 Apr;94(4):460-6
pubmed: 19965818
Ophthalmology. 2012 Mar;119(3):606-10
pubmed: 22226884
Clin Ophthalmol. 2012;6:447-52
pubmed: 22536035
Br J Ophthalmol. 2014 Feb;98(2):218-23
pubmed: 24169651
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
Br J Ophthalmol. 2009 Jan;93(1):40-4
pubmed: 18757470
Melanoma Res. 2019 Dec;29(6):655-659
pubmed: 30664105
Am J Ophthalmol. 2016 May;165:78-87
pubmed: 26940166
MAGMA. 2016 Jun;29(3):571-7
pubmed: 26915081
Arch Ophthalmol. 1990 Sep;108(9):1268-73
pubmed: 2205183
Int J Radiat Oncol Biol Phys. 1993 Jul 15;26(4):619-23
pubmed: 8330991
Radiol Med. 2017 Feb;122(2):131-139
pubmed: 27752969
Surv Ophthalmol. 1997 Nov-Dec;42(3):215-32
pubmed: 9406368
Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2085-93
pubmed: 11481276
Br J Ophthalmol. 2005 Jun;89(6):730-8
pubmed: 15923510
Am J Ophthalmol. 2000 Feb;129(2):199-204
pubmed: 10682973
Brachytherapy. 2011 Jul-Aug;10(4):331-9
pubmed: 21349775
Ophthalmol Retina. 2020 Sep;4(9):954-956
pubmed: 32595095
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):199-205
pubmed: 20675066
J Neurosurg. 2002 Dec;97(5 Suppl):635-9
pubmed: 12507111
Arch Ophthalmol. 1990 Feb;108(2):209-14
pubmed: 2302103
Ophthalmology. 1989 Sep;96(9):1377-82; discussion 1382-3
pubmed: 2550868
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Int J Radiat Oncol Biol Phys. 1989 Aug;17(2):365-9
pubmed: 2753760
Br J Ophthalmol. 2009 Sep;93(9):1172-6
pubmed: 19414441